Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: reply (21), answer (791), reaction (683)

AmB - Cytarabine(3000)

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA AmB- CYTARABINE (3000mg/m2) Ambulatory Regimen This regimen is for AMBULATOR
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AmB-Cytarabine-3000.pdf

People and OD Committee ToR September 2025

Description: People and Organisational Development Committee Terms of Reference Date Issued: 9 September 2025 Review Date: August 20
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/People-and-OD-Committee-ToR-September-2025.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) This regimen will onl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

Gender pay gap report 2024

Description: Gender Pay Gap. Our Gender Pay Gap at a Glance Snapshot from 31st March 2024 Our mean average gender pay gap
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Gender-pay-gap-report-2024.pdf

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen • Lung-Ate
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

End of life care strategy - patient information

Description: A strategy for end of life care.
Url: /Media/UHS-website-2019/Patientinformation/Bereavement-and-end-of-life/End-of-life-care-strategy-3687-PIL.pdf

People and OD Committee ToR September 2024

Description: People and Organisational Development Committee Terms of Reference Date Issued: 10 September 2024 Review Date: August 2
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/People-and-OD-Committee-ToR-September-2024.pdf

WDES report and action plan 2024

Description: Workforce Disability Equality Standard Annual Report 2024 1 Executive Summary The Workforce Disability Equality Stand
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/UHS-WDES-report-and-action-plan-2024.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDAR
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer –
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

281 to 290 of 398

Previous … 27 28 29 30 31 … Next